
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson reported operational sales growth of 11.5% in 4Q 2025, excluding the significant impact of generic competition affecting Stelara, indicating strong performance driven by its innovative medicine and medtech divisions. The company's updated revenue estimates for 2026 highlight projected total revenue of $100.42 billion, reflecting positive adjustments due to impressive growth in key products like Tremfya and Rybrevant. With JNJ's stock appreciating approximately 30% since July 2025 and the positive momentum expected to continue into 2026, the firm’s favorable outlook is supported by robust earnings revisions and a strong product pipeline.
Bears say
Johnson & Johnson faces significant challenges due to the impending loss of patent exclusivity, which typically results in rapid declines in sales as competitors introduce generics and biosimilars. The company’s outlook is further pressured by the potential disappointing launches of newer products and critical data readouts from its pipeline, which raise concerns about overall sales and earnings. Additionally, ongoing litigation risks, particularly regarding talc-related lawsuits, combined with macroeconomic uncertainties such as U.S. drug pricing reform, may deter investor interest and contribute to share volatility.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares